Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that GenSci128 received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer. The selective small-molecule TP53 Y220C reactivator, already in clinical trials for pancreatic, ovarian, breast, and colorectal cancers, now holds dual ODD status (pancreatic + gastric), validating its pan-tumor potential for the TP53 Y220C mutation across multiple solid malignancies.
Regulatory Milestone
Item
Detail
Agency
U.S. Food and Drug Administration (FDA)
Designation
Orphan Drug Designation (ODD) – gastric cancer indication
Favorable efficacy and safety profile demonstrated
TP53 Y220C Mutation Context
Parameter
Clinical Significance
Mutation Prevalence
~1–2% of solid tumors (~10,000–15,000 annual cases globally across indications)
Current Standard of Care
No approved targeted therapies; chemotherapy/immunotherapy with limited efficacy in TP53-mutant tumors
GenSci128 Differentiation
First-in-class selective Y220C reactivator; addresses “undruggable” p53 with structure-based drug design
Orphan Drug Value
7-year U.S. exclusivity, tax credits, waived FDA fees – critical for rare mutation subset
Strategic Context & Development Pathway
Factor
Implication
Dual ODD Strategy
Gastric + pancreatic designations cover highest-unmet-need GI malignancies; supports basket trial design across Y220C+ solid tumors
China-U.S. Parallel Development
NMPA and FDA IND approvals enable synchronized global trials; accelerates regulatory pathways
Companion Diagnostic
TP53 Y220C testing required for patient selection; partnership with NGS providers critical for commercialization
Revenue Potential
Niche but premium pricing (~$200,000–300,000 annually) in orphan indications; peak sales $300–500 million globally if approved in 2–3 tumor types
Clinical Timeline: Phase I dose-escalation ongoing; expansion cohorts in gastric/pancreatic cancer 2026–2027; potential breakthrough therapy designation application based on early efficacy signals
Competitive Landscape: PMV Pharma (PC14586) – competing Y220C reactivator in Phase I/II; GenSci128’s dual ODD + China-U.S. development provides differentiation
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical trial enrollment, efficacy outcomes in TP53 Y220C+ gastric cancer, and regulatory pathway acceleration for GenSci128. Actual results may differ due to mutation-specific patient identification challenges, competitive dynamics with other p53 reactivators, and reimbursement negotiations for ultra-rare mutation-targeted therapies.-Fineline Info & Tech
By Fineline Cube